Q3 earnings have increased year-on-year, fosun pharma promotes the sales of botulinum toxin products domestically | Direct coverage of the earnings conference.

① During the earnings conference, fosun pharma stated that the company's performance improved year-on-year in Q3 due to factors such as the continuous increase in innovative drug volume. ② Chief financial officer Chen Zhanyu revealed that the company is actively promoting the rapid上市 and sales of injectable type A botulinum toxin within china. ③ The privatization process of henlius and the accessibility of CAR-T products are also receiving significant attention.

cls.cnNov 13 21:52

Vitamin price increase dividend realized! zhejiang nhu Q3 net profit increased by nearly 190% year-on-year|interpretations

1. Zhejiang NHU and Zhejiang Garden Biopharmaceutical have seen a sharp increase in profits in Q3; 2. The rise in prices of vitamins has boosted manufacturers' performance; 3. Vitamin prices have declined from their peak, but still remain relatively high; 4. The price hike benefits will continue into Q4, but profit growth may slow down.

cls.cnOct 23 21:04

Net profit increased by over 268 times year-on-year! Semiconductor concept stocks disclosed the third-quarter report of 27.7 billion | Highlights of post-market announcements.

Suzhou Jinfu Technology: In the future, its subsidiary Maizhi Technology will actively communicate with various ODMs and cloud service manufacturers of NVIDIA to discuss potential equipment needs and order situations.

cls.cnOct 23 20:59

Zhejiang Hisun Pharmaceutical: Give up the pharmaceutical distribution raw material business, leading to a decline in H1 revenue. Sales of Olsalazine increased significantly compared to the same period last year.

①At the earnings conference, the CFO of Zhejiang Hisun Pharmaceutical explained that the decline in H1 revenue was due to the company's abandonment of low-margin pharmaceutical distribution raw material business and other factors. ②President Xiao Weihong addressed questions about the growth in endocrine drug revenue and the future business model of the animal health sector.

cls.cnSep 4 21:29

The decline in the pharmaceutical sector is affecting overall revenue. Fosun Pharma: Will focus on building super 1 billion yuan big varieties | Earnings conference highlights.

Fosun Pharma's revenue from innovative drugs in the first half of the year exceeded 3.7 billion yuan, accounting for about 18% of the overall revenue. Wu Yifang revealed that the business of innovative drugs will strive to achieve a compound annual growth rate of 30% in the next few years. Wu Yifang said that the privatization of Henlius is currently underway, and the entire business and pipeline of Henlius will be deeply integrated with Fosun Pharma through privatization.

cls.cnAug 29 07:29

How is the market outlook for vitamins? Zhejiang Nhu's Q2 net profit of 1.335 billion yuan hit a record high|Interpretations of financial reports

①The vitamin bull market significantly boosts manufacturers' performance; ②zhejiang nhu's Q2 net profit hits a record high for the same period in history; ③The company benefits from a high proportion of overseas business; ④The increase in the third quarter expands, further benefiting manufacturers.

cls.cnAug 22 21:50